Flupirtine Tablets: Clinical Guidance
Flupirtine has been withdrawn from most markets due to serious hepatotoxicity concerns and should NOT be used for postoperative pain management. While historical evidence showed efficacy for moderate acute pain, the drug's significant liver toxicity risk outweighs any potential benefits, and safer alternatives are readily available.
Critical Safety Information
The provided FDA label 1 appears to be for fluticasone propionate nasal spray, not flupirtine—this is a documentation error. Flupirtine is a non-opioid centrally-acting analgesic that was withdrawn from European markets in 2018 due to hepatotoxicity.
Hepatotoxicity Risk
- Severe liver injury including acute liver failure has been documented with flupirtine use
- Risk increases significantly with treatment duration >2 weeks 2
- Liver enzyme monitoring (AST/ALT) is mandatory if the drug is used at all 2
- The drug should never exceed 2 weeks of continuous use 2
Historical Dosing (For Reference Only)
When flupirtine was available, the regimen was:
Acute Pain:
- Initial dose: 100 mg orally every 8 hours 3, 4
- Alternative: 200 mg orally three times daily 5, 6
- Maximum daily dose: 600 mg 5, 6
- Rectal formulation: 150 mg suppositories every 8 hours 7
Duration: Limited to <14 days due to hepatotoxicity risk 2
Evidence Summary
Efficacy Data
Research showed flupirtine was:
- Comparable to diclofenac 50 mg and piroxicam 20 mg for postoperative pain, though with slower onset 3
- As effective as diclofenac for postcraniotomy pain (90.2% vs 90.5% pain relief) 4
- Equivalent to opioids (codeine, pentazocine) and NSAIDs for moderate acute pain 7, 5, 6
However, a 2023 meta-analysis of 13 RCTs (1,014 patients) concluded that flupirtine was NOT superior to other analgesics or placebo for postoperative pain and showed inferior pain control at 48 hours 8.
Side Effect Profile
- Most common: drowsiness (10%), dizziness, dry mouth, GI complaints 5, 6
- No respiratory depression (unlike opioids) 6
- No addiction potential 6
- Serious hepatotoxicity with prolonged use 2
Recommended Alternatives (Based on Guidelines)
Following current pain management guidelines 9, 10, 11:
For Moderate Acute Pain:
- First-line: NSAIDs (ibuprofen 600 mg every 6-8 hours, maximum 2400 mg/day) 12, 10
- Alternative: Acetaminophen 1000 mg every 4-6 hours (maximum 4000 mg/day) 13, 10
- Combination: NSAID + acetaminophen provides superior analgesia 9
For Severe Acute Pain:
- Opioids: Morphine, oxycodone, or hydromorphone as immediate-release formulations 9, 10, 11
- Duration: 3 days or less typically sufficient; rarely >7 days needed 9, 14
- Multimodal approach: Combine opioids with scheduled NSAIDs/acetaminophen 9
Postcraniotomy Pain Specifically:
- Diclofenac 50 mg every 8 hours is effective and well-studied 4
- Avoid NSAIDs if bleeding risk is elevated
Clinical Pitfalls
- Do not prescribe flupirtine if it remains available in your region—hepatotoxicity risk is unacceptable
- If a patient reports prior flupirtine use, check liver function tests
- For taxane-induced cancer pain, consider opioids or gabapentinoids rather than flupirtine 2
- The 2023 meta-analysis definitively shows flupirtine offers no advantage over standard analgesics 8
Bottom line: Use evidence-based alternatives (NSAIDs, acetaminophen, opioids when appropriate) that have established safety profiles and follow current CDC and WHO pain management guidelines 9, 10, 14.